While most cancer programs in the United States report that they employ advanced practitioners (APs), they are often not utilized to the full scope of their abilities in clinical research. In this episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, shares the evolution of the advanced practitioner role at her institution, where APs have a larger voice in the research process and clinical trial protocols, serve as champions to advocate for patients and research staff, and collaborate with their team to promote best practices in clinical trial delivery. Guest: Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN Nurse Practitioner Cleveland Clinic Cleveland, Ohio This is the third mini-podcast in a series, which highlights key takeaways from the spring 2021 ACCC-Harborside Virtual Summit to "Define the Role of Oncology Advanced Practitioners in Equitable Cancer Care Delivery." Related Content: -[MINI-PODCAST] Ep 60: Advancing Clinical Trial Equity -Paving the Way for APPs in Clinical Research [Oncology Issues article] -How Oncology Advanced Practitioners Can Enhance Community Oncology Research [On-demand webinar] -Disparities in Cancer Research: A Precursor to Disparate Cancer Outcomes: Health Equities -Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer -The Multi-Regional Clinical Trials Center of Brigham and Women's Hospital and Harvard developed a comprehensive guidance document and supplementary toolkit to enhance diversity in clinical trials. -ACCC Community Oncology Research Institute -ASCO-ACCC Initiative to Increase Racial and Ethnic Diversity in Clinical Trials -In Pursuit of Equity: Diversity in Clinical Research Participation [Webinar] -Practical Solutions to Better Engage Cancer Professionals with Communities of Color [Webinar]
